Notably, in a hypoxic microenvironment, Galectin-1 secreted by cancer-associated fibroblasts (CAFs) is further upregulated, which may drive the drug-resistant phenotype by activating the VEGF (27), suggesting its potential as a target for reversing rituximab resistance. This evidence concerns the gene LGALS1 and cancer.